Search

Your search keyword '"rare histology"' showing total 3 results
Start Over Descriptor "rare histology" Topic adenocarcinoma
3 results on '"rare histology"'

1. Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series.

Author

Omiya A, Nitta S, Kandori S, Takahashi R, Chihara I, Shiga M, Kojo K, Nagumo Y, Ikeda A, Kawahara T, Hoshi A, Mathis BJ, Negoro H, and Nishiyama H

Subjects
Humans, Retrospective Studies, Male, Middle Aged, Aged, Female, Tegafur administration & dosage, Tegafur therapeutic use, Oxonic Acid administration & dosage, Oxonic Acid therapeutic use, Treatment Outcome, Urologic Neoplasms drug therapy, Drug Combinations, Cisplatin administration & dosage, Cisplatin therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Adenocarcinoma drug therapy, Adenocarcinoma pathology
Abstract

Competing Interests: Disclosure The authors have no conflicts of interest to disclose.

Published
2024
Full Text
View/download PDF

2. Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities.

Author

Deuker, Marina, Martin, Thomas, Stolzenbach, Franziska, Rosiello, Giuseppe, Collà Ruvolo, Claudia, Nocera, Luigi, Zhe Tian, Becker, Andreas, Kluth, Luis, Roos, Frederik C., Tilki, Derya, Shariat, Shahrokh F., Black, Peter C., Kassouf, Wassim, Saad, Fred, Chun, Felix, and Karakiewicz, Pierre I.

Subjects
*BLADDER cancer, *TRANSITIONAL cell carcinoma, *SQUAMOUS cell carcinoma, *HISTOLOGY, *CYSTECTOMY
Abstract

Our aim was to examine 4 different non-urothelial variant histology (VH) bladder cancer types, relative to urothelial carcinoma of the urinary bladder (UCUB). We found that TNM stage at diagnosis was invariably more advanced in patients with VH bladder cancer versus patients with UCUB. Squamous cell carcinoma appeared to have the worst natural history. All other VH subgroups exhibited more aggressive natural history than UCUB in non-metastatic stages only. Background: The purpose of this study was to evaluate stage at presentation, treatment rates, and cancerspecific mortality (CSM) of non-urothelial variant histology (VH) bladder cancer (BCa) relative to urothelial carcinoma of the urinary bladder (UCUB). Materials and Methods: Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), patients with VH BCa and UCUB were identified. Stage at presentation and treatment rates, as well as multivariably adjusted and matched CSM rates according to TNM stage within each histologic subtype, were reported. Results: Of all 222,435 eligible patients with BCa, 11,147 (5.0%) harbored VH. Among those, squamous cell carcinoma accounted for 3666 (1.6%) patients, adenocarcinoma for 1862 (0.8%), neuroendocrine carcinoma for 1857 (0.8%), and other VH BCa for 3762 (1.7%) of the study cohort. Patients with VH BCa showed invariably more advanced TNM stage at presentation compared with patients with UCUB. Treatment rates according to TNM stages showed similar distribution of cystectomy rates in VH BCa and UCUB. However, important differences in the distribution of radiotherapy and chemotherapy rates existed within VH BCa and in comparison with UCUB. Furthermore, even after multivariable adjustment and matching with UCUB, squamous cell carcinoma exhibited higher CSM (hazard ratios, 1.43-1.95; all P < .01) across all stages. All other VH predominantly exhibited higher CSM than UCUB in either nonemuscle-invasive or muscle-invasive nonmetastatic stages. Conclusion: TNM stage at diagnosis is invariably more advanced in all patients with VH BCa versus patients with UCUB. Of all VH BCa, in multivariably adjusted stage for stage analyses, squamous cell carcinoma appears to have the worst natural history. All other VH subgroups exhibited more aggressive natural history than UCUB in nonmetastatic stages only. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

3. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

Author

Emma Zattarin, Giuseppe Viscardi, Elisa Sottotetti, A. Prelaj, Marta Brambilla, Giulia Galli, Riccardo Lobefaro, Monica Ganzinelli, Claudia Proto, Roberto Ferrara, Rosa Maria Di Mauro, Sara Manglaviti, Diego Signorelli, Marta Bini, Mario Occhipinti, Giuseppe Lo Russo, Giulia Apollonio, Giacomo Massa, Teresa Beninato, Filippo de Braud, Alessandra Fabbri, A. Bottiglieri, M.C. Garassino, Alessandro De Toma, and Benedetta Trevisan

Subjects
Pulmonary and Respiratory Medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Adenosquamous carcinoma, medicine.medical_treatment, Population, Uncommon NSCLC, Kaplan-Meier Estimate, Gastroenterology, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, 80 and over, Humans, ICIs, education, Sarcomatoid carcinoma, Lung cancer, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Not Otherwise Specified, Carcinoma, Histology, Immunotherapy, Middle Aged, medicine.disease, Survival Analysis, immunotherapy, lung cancer, rare histology, uncommon NSCLC, Rare histology, Oncology, Adenocarcinoma, Female, business
Abstract

Immune-checkpoint inhibitors (ICIs) have significantly improved outcome of advanced non-small cell lung cancer (aNSCLC) patients. However, their efficacy remains uncertain in uncommon histologies (UH).Data from ICI treated aNSCLC patients (April,2013-January,2021) in one Institution were retrospectively collected. Univariate and multivariate survival analyses were estimated by Kaplan-Meier and Cox proportional hazards regression model, respectively. Objective response rate (ORR) and disease control rate (DCR) were assessed.Of 375 patients, 79 (21.1%) had UH: 19 (24.1%) sarcomatoid carcinoma, 15 (19.0%) mucinous adenocarcinoma, 10 (12.6%) enteric adenocarcinoma, 8 (10.1%) adenocarcinoma not otherwise specified, 7 (8.9%) large-cell neuroendocrine carcinoma, 6 (7.6%) mixed histology non-adenosquamous, 5 (6.3%) adenosquamous carcinoma, 9 (11.4%) other UH. In UH group, programmed death-ligand 1 (PD-L1)1%, 1-49%, ≥50% and unknown expression were reported in 27.8%, 22.8%, 31.7% and 17.7% patients respectively and ICI was the second/further-line in the majority of patients. After a median follow-up of 35.64 months (m), median progression-free survival (mPFS) was 2.5 m in UH [95% CI 2.2-2.9 m] versus (vs.) 2.7 m in CH [95% CI 2.3-3.2 m, P-value = .584]; median overall survival (mOS) was 8.8 m [95% CI 4.9-12.6 m] vs. 9.7 m [95% CI 8.0-11.3 m, P-value = .653]. At multivariate analyses only ECOG PS was a confirmed prognostic factor in UH. ORR and DCR were 25.3% and 40.5% in UH vs. 21.6% and 49.5% in CH [P-value = .493 and .155 respectively].No significant differences were detected between UH and CH groups. Prospective trials are needed to understand ICIs role in UH population.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results